Brokerages Set Genmab A/S Sponsored ADR (NASDAQ:GMAB) PT at $39.25

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have received a consensus recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $39.25.

Several research firms have recently issued reports on GMAB. Johnson Rice reiterated a “buy” rating on shares of Genmab A/S in a report on Monday, October 27th. Weiss Ratings restated a “hold (c)” rating on shares of Genmab A/S in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Genmab A/S from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd. Truist Financial reissued a “buy” rating and set a $48.00 price objective (down previously from $49.00) on shares of Genmab A/S in a report on Thursday, November 6th. Finally, HC Wainwright restated a “buy” rating and issued a $39.00 target price on shares of Genmab A/S in a report on Wednesday.

Hedge Funds Weigh In On Genmab A/S

Hedge funds have recently made changes to their positions in the company. Founders Capital Management lifted its holdings in shares of Genmab A/S by 40.0% in the 4th quarter. Founders Capital Management now owns 1,400 shares of the company’s stock valued at $43,000 after purchasing an additional 400 shares during the last quarter. Parallel Advisors LLC increased its position in Genmab A/S by 11.3% during the third quarter. Parallel Advisors LLC now owns 4,139 shares of the company’s stock worth $127,000 after buying an additional 419 shares during the period. CWM LLC lifted its stake in Genmab A/S by 18.8% in the fourth quarter. CWM LLC now owns 2,739 shares of the company’s stock valued at $84,000 after buying an additional 433 shares during the last quarter. Jones Financial Companies Lllp boosted its holdings in shares of Genmab A/S by 29.1% in the third quarter. Jones Financial Companies Lllp now owns 1,951 shares of the company’s stock valued at $57,000 after acquiring an additional 440 shares during the period. Finally, Osaic Holdings Inc. boosted its holdings in shares of Genmab A/S by 37.8% in the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after acquiring an additional 440 shares during the period. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Trading Down 2.2%

Shares of GMAB opened at $32.63 on Friday. The firm has a market capitalization of $20.96 billion, a price-to-earnings ratio of 13.89, a PEG ratio of 19.53 and a beta of 0.90. The firm’s fifty day simple moving average is $32.47 and its 200-day simple moving average is $29.05. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $35.43.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Thursday, November 6th. The company reported $0.65 EPS for the quarter, beating the consensus estimate of $0.48 by $0.17. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%.The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $975.40 million. On average, analysts predict that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Key Stories Impacting Genmab A/S

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and $39 target while raising FY2025 estimates (now $2.00 EPS) and some near?term quarter forecasts, providing support under the stock. HC Wainwright Reiterates “Buy” Rating for Genmab A/S (NASDAQ:GMAB)
• Neutral Sentiment: Genmab disclosed grants of 32,806 restricted stock units and 34,307 warrants to employees — normal for biotech compensation but potentially modestly dilutive if exercised; not likely to be a major near?term earnings driver. Grant of Restricted Stock Units and Warrants to Employees in Genmab
• Neutral Sentiment: Reported short?interest data for January appears to show no meaningful or reliable change (entries show zero/NaN), so short covering is not a clear factor in today’s move.
• Negative Sentiment: HC Wainwright cut multiple 2026 quarterly and full?year EPS forecasts: FY2026 now $1.68 (was $2.14); Q4 2026 to $0.46 (from $0.63); Q1 2026 to $0.27 (from $0.34); Q2 2026 to $0.49 (from $0.58); Q3 2026 to $0.47 (from $0.59). Those downgrades lower near?term earnings visibility and are the primary reason investors are marking the stock down today.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.